Zacks Company Profile for Galena Biopharma, Inc. (SLS : NSDQ) |
|
|
|
Company Description |
SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.
Number of Employees: 11 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $3.46 |
Daily Weekly Monthly
 |
20 Day Moving Average: 203,946 shares |
Shares Outstanding: 20.54 (millions) |
Market Capitalization: $71.05 (millions) |
Beta: 1.74 |
52 Week High: $15.08 |
52 Week Low: $2.10 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
13.82% |
28.18% |
12 Week |
-41.36% |
-35.53% |
Year To Date |
-37.43% |
-20.46% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Angelos M. Stergiou - Chief Executive Officer and President
Jane Wasman - Chairman
John T. Burns - Chief Accounting Officer;Vice President
David Scheinberg - Director
Robert Van Nostrand - Director
|
|
Peer Information
Galena Biopharma, Inc. (CORR.)
Galena Biopharma, Inc. (RSPI)
Galena Biopharma, Inc. (CGXP)
Galena Biopharma, Inc. (BGEN)
Galena Biopharma, Inc. (GTBP)
Galena Biopharma, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 81642T209
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
|
|
Share - Related Items
Shares Outstanding: 20.54
Most Recent Split Date: 11.00 (0.02:1)
Beta: 1.74
Market Capitalization: $71.05 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-1.78 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/11/22 |
|
|
|
|